Could Systemic Inflammation-Based Prognostic ScoresPredict the Clinical Outcome in Patients with Breast CancerTreated with Everolimus Plus Exemestane?
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breastcancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFSand OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who hadbeen treated with everolimus plus exemestane.
Açıklama
Anahtar Kelimeler
Kaynak
Eurasian Journal of Medical Investigation
WoS Q Değeri
Scopus Q Değeri
Cilt
5
Sayı
2
